Pfizer Inc (PFE)

Working capital turnover

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Revenue US$ in thousands 58,496,000 100,330,000 81,288,000 41,651,000 50,108,000
Total current assets US$ in thousands 43,333,000 51,259,000 59,693,000 35,067,000 32,803,000
Total current liabilities US$ in thousands 47,794,000 42,138,000 42,671,000 25,920,000 37,304,000
Working capital turnover 11.00 4.78 4.55

December 31, 2023 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $58,496,000K ÷ ($43,333,000K – $47,794,000K)
= —

The working capital turnover of Pfizer Inc. has shown a fluctuating trend over the past five years. In 2020, the working capital turnover was 4.58, indicating that Pfizer generated $4.58 in revenue for every dollar of working capital invested in that year. This ratio increased to 4.78 in 2021, suggesting a slightly more efficient use of working capital compared to the previous year.

Notably, in 2022, Pfizer significantly improved its working capital turnover to 11.00, indicating a substantial increase in efficiency in utilizing its working capital to generate revenue. However, the working capital turnover for 2023 is not provided in the table for a direct comparison.

Overall, an increasing trend in the working capital turnover ratio signifies that Pfizer is becoming more efficient in utilizing its working capital to generate sales revenue, which is a positive indicator of the company's operational effectiveness.


Peer comparison

Dec 31, 2023


See also:

Pfizer Inc Working Capital Turnover